Blog

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia – Medical Xpress


Medical Xpress

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia
Medical Xpress
The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell receptors, or TCRs. This immunotherapy represents a different method of

and more »

2017-10-25 NEWS

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia – Medical Xpress


Medical Xpress

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia
Medical Xpress
The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell receptors, or TCRs. This immunotherapy represents a different method of

and more »

2017-10-25 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.